Sequel company Bonum emerges in wake of Roche’s Good Tx acquisition

Roche’s $250 million acquisition of one of Good Tx’s five conditionally activated cytokine programs will consolidate the pharma’s cancer immunotherapy strategy whilst leaving the biotech free to develop its platform technology in a new company, Bonum, which is working on raising a series A.

Announced Wednesday, Roche (SIX:ROG; OTCQX:RHHBY) is paying $250 million upfront for rights to the PD-1-regulated IL-2 program from Good Therapeutics Inc., and an exclusive right to the biotech’s platform technology for the development of additional PD-1-regulated IL-2 receptor agonists. Good Tx is also eligible for milestone payments under the deal, which is expected to close in 3Q22. ...